- Global Pharma News & Resources

Ulcerative Colitis Market Scenario 2020 – Current Trends, Size, Share and Future Opportunities by 2026

Global Ulcerative Colitis Market – Insights

Ulcerative colitis (UC), also known as colitis ulcerosa, is a chronic, inflammatory bowel disease that causes inflammation in the digestive tract. It is characterized by diarrhea, sudden and unexplained weight loss, loss of appetite, belly pain/cramps, bleeding from the rectum, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The inflammation results in development of tiny sores known as ulcers. Although the exact cause for UC is not known, probable factors include, genetic aspects, environmental changes, or weakened immune system. Healthy diet, proper hydration, skipping fatty foods, and limited consumption of high-fiber food can help to prevent UC. Although the incidence of the disease is high among people under 30 years of age, it may impact people of any age.

Request for the trending sample of this report:

Colonoscopy, endoscopy, biopsy, CT scan, and blood test are some of the diagnostic methods of the disease. A patient may suffer from colon cancer if ulcerative colitis persists for over 8 years or longer. Over-the-counter drugs such as Imodium therapy, steroid medicines, and amino salicylates can be used for the treatment of cases with mild symptoms. Surgery is recommended in severe cases to remove the colon. Moreover, some genetically engineered drugs approved by the U.S. Food and Drugs Administration (FDA) such as Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade), and Vedolizumab (Entyvio) are used for the treatment of UC. These drugs made up of certain living organisms target the inflammatory proteins such as cytokines to suppress the inflammation. However, these drugs have some side effects such as low blood pressure, breathing difficulties, fever, headache, hives, back pain, stomach pain, and weakening of the immune system. Some of the major drugs used to reduce inflammation and swelling and for the treatment of UC include, Sulfasalazine (Azulfidine), Mesalamine (Asacol and Lialda), Balsalazide (Colazal), and Olsalazine (Dipentum), Inflectra, Remsima, Adalimumab (Humira), and Infliximab (Remicade).

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Global Ulcerative Colitis Market Taxonomy:

Global Ulcerative Colitis Market by Drug Type

  • Infliximab
  • Golimumab
  • Adalimumab
  • Vedolizumab
  • Mesalamine
  • Budesonide
  • Balsazide

Global Ulcerative Colitis Market by Dosage Form

  • Parenteral
  • Oral

Global Ulcerative Colitis Market by Region

  • North America
  • Latin America
  • Asia Pacific
  • Middle East
  • Africa

Global Ulcerative Colitis Market: Drivers

Increasing incidence of UC is expected to boost growth of the global ulcerative colitis market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), the prevalence of UC is around 2.2 to 14.3 cases per 100,000 population per year. Moreover, according to a study conducted in 2014 by Crohn’s & Colitis Foundation of America (CCFA), 907,000 people suffered from UC in the U.S. (data based on the research conducted in between 2011-2014 by CCFA). According to the same source, the cases of UC are high in developed countries and the incidence of the disease is higher in urban areas compared to rural areas. Although, the disease can affect any age group, majority of the cases are between 15 to 35 years of age. According the stats of World Gastroenterology Organization (WGO), the prevalence of UC is increasing in emerging economies such as India, owing to changing diet and lifestyle.

Global Ulcerative Colitis Market: Regional Analysis 

According to data collected from various sources and compiled by Coherent Market Insights, Europe has the highest annual rate of incidence of UC worldwide, followed by North America. The rate is the lowest in Asia Pacific and Middle East. North America is expected to hold dominant position in the global ulcerative colitis market over the forecast period. This is attributed to increasing R&D in drugs and awareness regarding the treatment of the disease.

To understand Research Methodology, please click

Asia Pacific is expected to witness significant growth in the global ulcerative colitis market during the forecast period. This is attributed to increase prevalence of UC, R&D of new drugs, increasing awareness about the treatment of the disease, and loss of patent. For instance, Humira (adalimumab) lost its patent in 2016 and Remicade is expected to lose its patent in 2018. In 2016, India-based Torrent Pharmaceuticals launched a biosimilar drug under the brand name Adfra to compete Humira. Humira is a trade name for adalimumab medication owned by AbbVie Inc.

Global Ulcerative Colitis Market: Competitive Landscape 

Key players in the market are focused on R&D of novel drugs to expand their product portfolio. For instance, in October 2018, Pfizer, Inc.’s Xeljanz, an oral Janus kinase inhibitor showed effectiveness and safety in the treatment of ulcerative colitis in a 24-month open label extension study. In March 2019, The Janssen Pharmaceutical Companies of Johnson & Johnson announced the Phase III data UNFI study data for Stelara, a subcutaneous maintenance therapy, which showed positive results as maintenance therapy in adults suffering from moderate to severe UC. In August 2019, Takeda Pharmaceutical Company Limited, submitted new drug application (NDA) to Ministry of Health, Labor and Welfare in Japan for subcutaneous formulation of vedolizumab, which will be used as maintenance therapy in adults with moderate to severe UC.

Major players operating in the global ulcerative colitis market include Johnson and Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Hospira, Celltrion Healthcare, Warner Chilcott, Janssen Pharmaceuticals Inc., and Takeda Pharmaceuticals Company Ltd.

Table of Content

Global Ulcerative Colitis Market Research Report
Section 1: Global Ulcerative Colitis Industry Overview
Section 2: Global Economic Impact on Ulcerative Colitis Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Ulcerative Colitis Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Ulcerative Colitis Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 02-Mar-2021